Form 8-K LABORATORY CORP OF AMERI For: Jan 06
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.��20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
January�6, 2015
(Date of earliest event reported)
LABORATORY CORPORATION OF
AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
358 South Main Street, | � | � | ||
Burlington, North Carolina | 27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) | (Registrants telephone number including area code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 7.01 | Regulation FD Disclosure | |
On January 6, 2015, Laboratory Corporation of America� Holdings (LabCorp�) (NYSE: LH) announced that that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorps presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST).
A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.
Exhibits
99.1 | Press Release dated�January 6, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
� | By: | /s/ F. SAMUEL EBERTS III | |
� | � | F. Samuel Eberts III | |
� | � | Chief Legal Officer and Secretary | |
January�6, 2015
Exhibit 99.1
FOR IMMEDIATE RELEASE
Investor/Media Contact:
Stephen Anderson - 336-436-5076
Company Information: www.labcorp.com
358 South Main Street
Burlington, NC 27215
Telephone: (336) 584-5171
LABCORP IS SCHEDULED TO PRESENT AT THE
33RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Burlington, NC, January 6, 2015 - Laboratory Corporation of America� Holdings (LabCorp�) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorps presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST).
A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.
About LabCorp������� �
Laboratory Corporation of America� Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our website at: www.labcorp.com.
This press release contains forward-looking statements including with respect to estimated 2014 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorps operating and financial results is included in the Companys Form 10-K for the year ended December 31, 2013, including under the heading risk factors, and in the Companys other filings with the SEC. The information in this press release should be read in conjunction with a review of the Companys filings with the SEC including the information in the section of the Companys Form 10-K for the year ended December 31, 2013 and subsequent Forms 10-Q under the heading MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
- Peralta Community College District Seeks More Outstanding Leaders
- FendX Announces Corporate Update
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
